CTGF deficiency predisposes to aneurysm generation and rupture. Mineralocorticoid antagonist as potential therapeutic treatment

Autor:	Antonio Tejera-Muñoz, Alberto Ortiz, Pablo Cannata-Ortiz, Macarena Orejudo, Roel Goldschmeding, L.B. Steffensen, Marta Ruiz-Ortega, Z. Mallat, Lucas L. Falke, Rafael Selgas, Jesús Egido, Vanesa Esteban, Raúl R. Rodrigues-Diez, Ana M. Briones, Sandra Rayego-Mateos, Raquel Rodrigues-Díez
Rok vydání:	2021
Předmět:	CTGF Aneurysm business.industry Mineralocorticoid medicine.drug_class Therapeutic treatment medicine Cancer research Antagonist Cardiology and Cardiovascular Medicine medicine.disease business
Zdroj:	Tejera-Munoz, A, Rodrigues-Diez, R R, Esteban, V, Steffensen, L B, Rodrigues-Diez, R, Orejudo, M, Rayego-Mateos, S, Falke, L L, Cannata-Ortiz, P, Ortiz, A, Egido, J, Mallat, Z, Briones, A M, Selgas, R, Goldschmeding, R & Ruiz-Ortega, M 2021, ' CTGF deficiency predisposes to aneurysm generation and rupture. Mineralocorticoid antagonist as potential therapeutic treatment ', Atherosclerosis, vol. 331, pp. E246-E247 . https://doi.org/10.1016/j.atherosclerosis.2021.06.754
ISSN:	0021-9150
DOI:	10.1016/j.atherosclerosis.2021.06.754
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c228fc2bead1bea81a31f9ceafd99314 https://doi.org/10.1016/j.atherosclerosis.2021.06.754 Zobrazit plný text záznamu Full Text from ScienceDirect